EAU 2013 - Programme Book - YouMed

ESU Courses, 16 March
ESU Course 3
14.30 - 17.30 Metastatic prostate cancer
Green Hall 3 - Level N-1
Chair: K. Pummer, Graz (AT)
First and second line hormonal therapy: What should be considered?
K. Miller, Berlin (DE)
What is the role of chemotherapy and immunotherapy in patients with CRPC?
G. Mickisch, Bremen (DE)
New therapeutic options for patients with CRPC – more possibilities, more questions?
K. Pummer, Graz (AT)
Case discussion
G. Mickisch, Bremen (DE)
K. Miller, Berlin (DE)
K. Pummer, Graz (AT)
Aims and objectives
The aim of this course is to provide comprehensive state-of-the-art information about the optimal
management of patients with metastatic prostate cancer.
The first lecture will give an overview of the various forms of currently available androgen deprivation
therapies such as LHRH analogs and antagonists, address the potential advantages or disadvantages of
intermittent treatment, as well as outline the optimal timing of hormonal therapy. In addition, the role of
possible second-line hormonal manipulations will be presented.
The second lecture will present and critically discuss the role of chemotherapy as well as immunotherapy
at the time when hormone resistance has developed with a special emphasis on efficacy, side effects,
sequencing and patients` selection.
The third lecture will address recent achievements as well as future challenges by reviewing the mode of
action and the current role of newer therapeutic options such as testosterone synthesis inhibitors, androgen
receptor antagonists, or radionuclide therapy.
At the end of the course, interactive cases will be discussed together with the audience and there will be
plenty of time for questions and answers.
Registration fee excluding VAT
EAU members € 47
Non-EAU members € 69
Residents (members/non-members) € 21
EAU Milan 2013
323
ESU Courses